TaiMed Biologics Inc 4147
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- —
- Day Range
- —–—
- 52-Week Range
- —–—
- Bid/Ask
- — / —
- Market Cap
- —
- Volume/Avg
- — / —
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 37.91
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
TaiMed Biologics Inc is a Taiwan-based biotechnology company. It is engaged in the discovery, development, and delivery of medicines for infectious disease. It capitalizes on its intellectual, extensive expertise, and management resources to develop a health-care product pipeline that benefits patients, rewards investors, and propels to prominence in the biotechnology industry. The company's products pipeline includes TMB-365, VRC07-523LS, and others.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 23
- Website
- http://www.taimedbiologics.com
Comparables
Valuation
|
Metric
|
4147
|
6885
|
6696
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 5.65 | 2.06 | 3.52 |
Price/Sales | 37.91 | — | — |
Price/Cash Flow | 212.43 | — | — |
Price/Earnings
4147
6885
6696
Financial Strength
|
Metric
|
4147
|
6885
|
6696
|
|---|---|---|---|
Quick Ratio | 2.25 | 40.47 | 13.67 |
Current Ratio | 5.96 | 40.74 | 14.10 |
Interest Coverage | −12.72 | −4,668.87 | −647.17 |
Quick Ratio
4147
6885
6696
Profitability
|
Metric
|
4147
|
6885
|
6696
|
|---|---|---|---|
Return on Assets (Normalized) | −3.79% | −54.88% | −37.22% |
Return on Equity (Normalized) | −5.75% | −56.32% | −61.30% |
Return on Invested Capital (Normalized) | −4.28% | −57.95% | −39.00% |
Return on Assets
4147
6885
6696
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Lrlyhzbqsp | Ltk | $586.1 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Cmllrjfg | Wfqms | $113.7 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Hbvphyfv | Qrwzfv | $108.2 Bil | |
MRNA
| Moderna Inc | Cpwmpkdjr | Nqdh | $50.9 Bil | |
ARGX
| argenx SE ADR | Hvbyxply | Xlvm | $22.0 Bil | |
BNTX
| BioNTech SE ADR | Zzvrsvgq | Nrln | $21.8 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Sxllwjwyv | Mnnwblw | $18.9 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Lvddwtdyc | Yxjtpy | $14.6 Bil | |
INCY
| Incyte Corp | Jxxqlzb | Byxztdn | $12.8 Bil | |
RPRX
| Royalty Pharma PLC Class A | Xdrmfsllm | Bggfcb | $12.3 Bil |